Video

More Research is Needed to Prevent Late-Stage Diagnosis of Ovarian Cancer

A gynecologic-oncology clinical nurse specialist and one of this year’s CURE Ovarian Cancer Heroes discussed the lack of resources for patients with ovarian cancer and the need for more research.

Of the many challenges facing patients with ovarian cancer, one of the biggest is late-stage or delayed diagnosis due to the disease’s subtle signs and symptoms, according to Paula Anastasia RN, MN, AOCN.

At CURE’s Ovarian Cancer Heroes event, Anastasia — one of this year’s winners who works at the David Geffen School of Medicine at UCLA – discussed some of the resources that are lacking for patients with ovarian cancer.

“It is unfortunately one of the most fatal (forms of cancer) because it is diagnosed in the late stages,” said Anastasia, who has been a gynecologic-oncology clinical nurse specialist for more than 25 years. “The reason is there is not enough information on the signs and symptoms.”

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
Image of man with text.
An expert highlights the impact of anemia in myelofibrosis and presented Ojjaara as a possible treatment to reduce transfusions and improve outcomes.
After ovarian cancer surgery, Mary Barbera spent three months in rehab before finally returning home, a milestone that marked her emotional recovery.
Terry Gillespie said the hardest parts of her cancer journey were the isolation, the impact of chemotherapy, and how unprepared she felt despite good guidance.
Dr. Erika Hamilton says social media and professional guidelines help patients stay informed about fast-changing breast cancer treatments and advances.
Outpatient CAR T-cell therapy has reduced hospital stays by two-thirds while maintaining safety for those with blood cancers, according to Dr. Olalekan Oluwole.
Dr. Masey Ross explains how biomarker testing, patient history, and quality-of-life concerns guide treatment decisions in metastatic breast cancer.
Dr. Paolo Tarantino shares how antibody-drug conjugates deliver more targeted chemo, and how the treatment lasts longer in the body vs traditional therapy.
Image of women with text.
The inMIND trial led to the FDA approval of Monjuvi with Revlimid and Rituxan for relapsed follicular lymphoma, showing benefits across diverse patients.
Related Content